Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone

Status Completed

Clinical Trial Summary

RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's bone marrow. The donated bone marrow stem cells may replace the patient's immune system and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before or after transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide in treating patients who are undergoing a donor bone marrow transplant for Fanconi's anemia.

Clinical Trial Description

OBJECTIVES:

- Decrease the conditioning-related toxicity of cyclophosphamide without decreasing the engraftment rate to < 90% in patients undergoing allogeneic bone marrow transplantation for Fanconi's anemia.

OUTLINE: This is a multicenter, dose-finding study of cyclophosphamide.

- Nonmyeloablative conditioning regimen: Patients receive cyclophosphamide IV on days -5 to -2.

Cohorts of 5-10 patients receive decreasing doses of cyclophosphamide until the optimal dose (OD) is determined. The OD is defined as the dose at which ≥ 4 of 5 patients achieve engraftment and < 1 of 10 patients experiences dose-limiting toxicity.

- Allogeneic bone marrow transplantation (BMT): Patients undergo allogeneic BMT on day 0.

- Graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine orally or IV twice daily beginning on day -1 and continuing until day 49, followed by a taper on days 50-180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study. ;

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00317876
Study type	Interventional
Source	Fred Hutchinson Cancer Research Center
Contact
Status	Completed
Phase	Phase 1
Start date	June 1998

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02931071` - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1	Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00084695` - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT01146210` - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	N/A
Completed	`NCT01082133` - Multicenter Transplant Study for Fanconi Anemia	Phase 2
Completed	`NCT00965666` - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia	Early Phase 1
Terminated	`NCT00290628` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A
Recruiting	`NCT00027274` - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated	`NCT01001598` - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita	Phase 1/Phase 2
Recruiting	`NCT03206086` - Eltrombopag for People With Fanconi Anemia	Phase 2
Recruiting	`NCT03579875` - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders	Phase 2
Recruiting	`NCT05598515` - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia	N/A
Active, not recruiting	`NCT03476330` - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia	Phase 2
Terminated	`NCT05910853` - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed	`NCT03609840` - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT00479115` - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	Phase 1/Phase 2
Completed	`NCT00352976` - TBI Dose De-escalation for Fanconi Anemia	Phase 2/Phase 3
Terminated	`NCT03600909` - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms